{"id":616871,"title":"Health Canada Policy Position Paper – Autologous Cell Therapy Products - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-03-03","captureTimestamp":"2026-03-03T01:10:25.661000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html","snippet":"Health Canada Policy Position Paper – Autologous Cell Therapy Products Purpose Many emerging autologous Footnote 1 cell therapy products may eventually prove to be safe and effective. However, most of these products are currently at the investigational stage of development with…","rawSnapshotUrl":"/api/snapshots/raw/616871","browseUrl":"https://replay.healtharchive.ca/job-6/20260303011025/https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html#ha_snapshot=616871","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}